Our Science
The blueprint was always there.
It took 30 years of science to read it.
Every company developing in vivo cell therapy is using technology that was built for something else. CAR constructs adapted from ex vivo therapy. Delivery vectors borrowed from gene therapy. The field has been innovating around a broken foundation instead of replacing it.
Modulari-T built two things from scratch: a next-generation receptor that mirrors the natural architecture of immune cells, and a modular delivery vehicle purpose-designed for in vivo targeting. Together, they form the only complete 2nd generation in vivo CGT system in existence.
The only company that has developed both the receptor AND the delivery vehicle from scratch.
MARC – Modular Actuation Receptor Complex
Modulari-T’s proprietary MARC platform was purposefully designed to expand the power and reach of cell therapies
Receptor MODULARITY is CRITICAL to signaling integrity
The MARCs recreate the natural architecture and signaling of immune receptors to safely and efficiently direct the immune response
MARCs will allow the expansion of the CAR-T market to more patients and new indications
Modular Actuation Receptor Complex (MARC)
Modular complex
with separate
targeting and
signaling modules
Powerful
signalling
fully activates
cells
ON when
triggered and
OFF when
recycled
Antibody-based target interaction
Multiple signal outputs
The groundbreaking modular design of the MARC system offers unprecedented opportunity in unlocking next-generation cell therapies
Modulari-T has generated and validated MARCs across diverse cell types and modalities:
Logic-gated target binding
tuned for pH sensitivity and target expression levels
Bispecific receptors
to prevent antigen escape
Novel signaling modalities
to expand therapeutic reach
Going further to rewire non-immune cells like adipocytes, neurons, and epithelial cells
Moving beyond T cell modulation into NK cells, B cells and T regulatory cells
Immune Cell (Subset)
Non-Immune Cell (Subset)
ph-sensitive activation
Enhanced adhesion
Bispecific recognition
Proliferation activation
Metabollic tuning
Anti- inflammatory
MARCs outperform CARs on efficacy, safety & targeting by unleashing the power of immune cells and creating a broader range of TAAs
MARCs can differentiate
between normal and overexpression of solid tumor antigens, expanding TAAs
Reduced exhaustion
MARC-T cells proliferate longer, preserve a better phenotype and accumulate fewer exhaustion markers
Persistent response
MARC-T provides a persistent response and prevents relapse even upon redosing
Improved Safety
MARC-T cells secrete significantly less of the toxic cytokines involved in cytokine release syndrome (CRS)
MoVe – Modular Vector
Modular Vectors (MoVe)s are First-in-Class rationally designed delivery vehicles for In Vivo Therapies
MoVes were designed to avoid the limitations of traditional, off-the-shelf lentiviral and adenoviral approaches, which show poor safety and efficacy
Competing in vivo
technology only efficiently
targets T cells
MoVes can target a broad
range of immune and
non-immune cells via
custom promoters
Bispecific MoVes can
simultaneously target T, NK and NKT cells to enable a
combined innate and adaptive immune response.
Genetic cargo can be
permanently integrated or
expressed in a transient
manner using inactivated
vectors
MoVes can deliver partner technology or other genetic payloads (e.g. gene therapy)
Modular Vector (MoVe) are proprietary de-targeted viral vectors that are re-engineered with custom modular envelopes for selective entry into target cells for in vivo cell and gene therapy delivery
MoVe technology allows for efficient and robust delivery of MARCs, and other payload formats (Gene therapy, IPSC, HSCT) for scalable, in vivo and off-the-shelf therapy
MoVes are significantly more versatile, efficient and manufacturable compared to competitors, which rely on older, generic delivery vehicles
MoVes significantly and more efficiently transduce both T and NK cells to generate active therapeutic cells
Compared to competitors, MoVes show best-in-class versatility, activation and therapeutic potential
The MoVe has best-in-class specificity to reduce the off-targets effects that limit LVs and LNP vectors relied on by competitors